Ascelia Pharma AB (publ) Stock Price

OM:ACE Community·SEK 408.3m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
6 Fair Values set on narratives written by author

Create a narrative

ACE Share Price Performance

SEK 0

-2.92 (-100.00%)

SEK 0

-2.92 (-100.00%)

SEK 0

Tue, 30 Dec 25

Share Pricen/a

ACE Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

High growth potential with excellent balance sheet.

3 Risks

2 Rewards

View Full Analysis

Ascelia Pharma AB (publ) Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

Feb 05, 2026

: -0.70
: 0%
: 0%
: 0%

View Full Analysis

About ACE

Founded: 1999
Employees: 11
CEO: Magnus Corfitzen
WebsiteView website: www.ascelia.com

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.